



## **eureKARE launches with \$60 million to build and finance next generation biotech companies in Europe**

*\$60 million Series A capital to finance and build disruptive European biotechnology companies in two cutting-edge fields of research: the microbiome and synthetic biology*

*Biotech start-up studio model to select and nurture high quality European innovation with revolutionary potential to maximise opportunities for investors and scientists for the benefit of patients*

*eureKARE is guided by influential founder, Alexandre Mouradian, accompanied by a highly skilled team and an international Scientific Advisory Board of renowned experts*

**Paris, France – 18 May 2021:** eureKARE ("the Company"), a pioneering new company focused on financing and building next generation biotechnology companies in the disruptive fields of the microbiome and synthetic biology, today announces its launch with a \$60 million Series A financing. The financing was supported by high-net worth investors and family offices.

eureKARE is focused on two emerging and cutting-edge fields of research that have the potential to disrupt and revolutionize the life sciences industry: the microbiome and synthetic biology. Up to 90% of all diseases can be linked to the dysfunction and imbalance of the microbiome with the field forecast to reach \$1.6 billion by 2028 at a CAGR of 21%. Synthetic biology, which comprises gene and cell therapy and industrial applications such as data storage and bioproduction, has seen huge advances in recent years and is expected to have far-reaching implications on the life sciences and other industries and for patients. It is forecast to reach \$57 billion by 2028 at a CAGR of 25% per year. Gene therapies alone already generate c.\$4 billion revenues with huge potential in gene editing, siRNA, mRNA, and is forecast to reach c.\$10 billion by 2028.

Europe's scientists are at the forefront of microbiome and synthetic biology research due to the innovative work and thought leadership taking place at prestigious universities and research centers. eureKARE believes there is a tremendous opportunity to industrialize this translational research by building bridges between academia and industry.

**Rodolphe Besserve, Chief Executive Officer of eureKARE, commented:** *"European science remains under exploited compared to countries like the US, with the gap between academia and big pharma widening over the years. eureKARE aims to build bridges between these two bodies to create and support new ventures. eureKARE has assembled an expert team and, together with our top-notch Scientific Advisory Board, we want to create a unique ecosystem of ideation and cross-fertilization of expertise to build successful companies."*

eureKARE has a two-step investment approach to deliver long-term value creation built around the two major inflection points in pharmaceutical development. The Company supports translational research by creating and financing new companies out of high value European science through its biotech start-up studios eureKABIOME (Microbiome) and eureKASYNBIO (Synthetic biology). These

studios are designed to select and nurture high quality European science and create a unique ecosystem, putting resources and expertise behind scientists and concepts to create new companies. The Company also intends to invest in more mature biotech companies (Series B or after) and will systematically propose to offer some liquidity to early investors, thereby addressing a critical need in the European biotech field.

eureKARE will create 3-5 new ventures a year and invest in 3-5 existing companies. This perfect mix of early-stage ventures with high growth potential and more mature de-risked companies mitigates risk for shareholders.

eureKARE has a rapidly growing portfolio comprising three exciting ventures to date: Stellate Therapeutics in the gut-brain axis field, the XNA technology company Omne Possibile and NovoBiome, a discovery platform dedicated to the gut-liver axis.

“Each of these companies has the potential to offer disruptive solutions in its chosen domain. These are perfect examples of what eureKARE wants to do. Thinking outside the box is in our DNA. The rapid COVID-19 vaccine development has shown the power of human ingenuity and this model will be a core inspiration for us as we progress,” **added Rodolphe Besserve.**

eureKARE is guided by influential founder, Alexandre Mouradian, along with a pan-European team led by renowned biotech expert Rodolphe Besserve. eureKARE’s Scientific Advisory Board is composed of eight international leading lights in their respected knowledge base, who will support the company in all of its strategic and investment decisions.

**Commenting on the launch, Alexandre Mouradian, Founder & Chairman of eureKARE, said:** *“Europe is at the forefront of microbiome and synthetic biology research and it is vital to find innovative new investment approaches to support the next wave of life science entrepreneurs. Through eureKARE’s pioneering approach, we are poised to identify, select and nurture the very best European science to create exciting new companies with the potential to disrupt and revolutionize the life sciences industry for the benefit of patients, while delivering shareholder value.”*

**-End-**

#### **About eureKARE**

eureKARE is a pioneering new company focused on financing and building next generation biotechnology companies in the cutting-edge fields of the microbiome and synthetic biology. eureKARE has a two-step investment approach to deliver long-term value creation. The Company supports translational research by creating and financing new companies out of high value European science through its biotech start-up studios eureKABIOME (Microbiome) and eureKASYNBIO (Synthetic biology). The Company also intends to invest in more mature biotech companies and will systematically propose to offer some liquidity to early investors, thereby addressing a critical need in the European biotech field. Guided by its influential founder, Alexandre Mouradian, and a pan-European team, eureKARE has a rapidly growing portfolio of companies that have the potential to disrupt the life sciences industry.

eureKARE is headquartered in Luxembourg, with a presence in France & Belgium. For more information visit: <https://eurekare.eu/>

### **About NovoBiome**

NovoBiome is a drug discovery company focused on the critical nexus of liver, intestinal diseases and the gut microbiome. It is developing breakthrough Live Biotherapeutics Products (LBPs), a novel and emerging class of drugs containing living micro-organisms that have a positive influence on the health and physiology of the host. NovoBiome's first LBP drug candidate, ADC-001, targets potential first-in-class therapies for hepatic conditions such as Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato-Hepatitis (NASH). The Company is developing an *ex-vivo* research and discovery platform, NovoSift®, designed to mimic human intestinal physiology that will unlock new insights into disease pathophysiology, novel drug targets, compounds and LBP drug candidates.

NovoBiome is headquartered in France. For more information, please visit: [www.novobiome.eu](http://www.novobiome.eu)

### **About Omne Possibile**

Omne Possibile is a pioneering, global technological leader in XNA, creating customizable structures to outperform current DNA and RNA technologies. Its goal is to harness the transformative power of XNA in areas including healthcare, information technology and smart materials. The Company's initial focus is on development of XNA polymers for information storage and XNA building blocks for improved messenger therapeutics. Omne Possibile has R&D hubs in Leuven, Belgium, and Basel, Switzerland. It was founded by leading European synthetic biologists and is supported by a world class scientific advisory board.

For more information, please visit [www.omnepossibile.com](http://www.omnepossibile.com)

### **About Stellate Therapeutics**

Stellate Therapeutics is a private global biotechnology company that develops small molecules produced by the microbiome into first-in-class therapies for neurological diseases (Parkinson and Alzheimer diseases). Stellate is also evaluating a portfolio of new drug candidates in other conditions, with capabilities across discovery, screening, production and diagnostic development.

For more information, visit [www.stellate-tx.com](http://www.stellate-tx.com).

### **Contact**

#### **eureKARE SA**

Marina Shapochnik, Head Investor Relations  
[marina.shapochnik@eurekare.eu](mailto:marina.shapochnik@eurekare.eu)

#### **Consilium Strategic Communications**

Amber Fennell, Jonathan Birt, Melissa Gardiner, Carina Jurs  
+44 (0) 203 709 5000  
[eurekare@consilium-comms.com](mailto:eurekare@consilium-comms.com)